Radar · Neurology in New York
Best Neurology Companies in New York, United States
The 109 best Neurology companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LEXEO Therapeutics.
By Riya SenguptaFinancials
109companies tracked
$2.2Bdisclosed funding
0unicorns
62have raised
FLIAR INTELLIGENCE · NEUROLOGY × NEW YORK
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
293kcombined LinkedIn audience
42%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Neurology companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | LEXEO Therapeutics Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases 29Funding top 19%News top 43%Growth top 47%Tech bottom 49% All 9 signals ▾Fundingtop 19% Newstop 43% Growthtop 47% Techbottom 49% Talentbottom 40% Globalbottom 39% Marketbottom 31% Moatbottom 31% Fin. healthbottom 29% Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $185M | 8 mo ago | 58 58 → 97 (+67%) · sector median +18% | Nolan Townsend CEO | DrupalPHPGoogle Maps+19 | — | 1 launch |
| 2 | Precision Neuroscience Developed of brain-computer interface tool for medical treatment and drug development 50Funding top 18%Moat top 31%Talent top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 31% Talenttop 38% Techtop 39% AItop 45% Growthbottom 40% Globalbottom 37% Marketbottom 34% Newsbottom 18% Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $174M | 7 mo ago | 22 | Benjamin Rapoport Co-Founder & CSO | SanityTurbopackApple iCloud Mail+21 | — | 1 job opening · 2 launchs · 1 award |
| 3 | Synchron Developer of implantable bioelectronics for the treatment of neurological conditions 48Funding top 17%News top 30%Talent top 38%Growth top 47% All 8 signals ▾Fundingtop 17% Newstop 30% Talenttop 38% Growthtop 47% Moattop 48% Marketbottom 46% Globalbottom 39% Techbottom 35% Funding: Raised $145M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) News: 3 BI events in 12 mo (of 14 tracked, 7 types) · Top themes: Funding, Capital raise rank vs industry peers · Fliar Intelligence Index 48/100 | $145M | 7 mo ago | 53 53 → 130 (+145%) · sector median +18% | Rahul Sharma Co-Founder | Craft CMSApple iCloud MailPHP+13 | — | 2 job openings |
| 4 | LB Pharmaceuticals Developer of small molecule based therapeutics for schizophrenia 67Moat top 21%Growth top 23%Patents top 25%News top 27% All 10 signals ▾Moattop 21% Growthtop 23% Patentstop 25% Newstop 27% Fundingtop 30% Innovationtop 34% Talenttop 41% Marketbottom 44% Globalbottom 43% Partnersbottom 35% Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $130M | 4 mo ago | — | Zachary Prensky Founder & CEO | — | 437 patents Small-molecule immunomodulators targeting CXCR4/CXCR2, BTK, complement, and IL-6 pathways | — |
| 5 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | 358 358 → 419 (+17%) · sector median +18% | — | DrupalApple iCloud MailPHP+26 | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 6 | Prevail Therapeutics Developer of gene therapies for treating neurodegenerative and rare diseases | $125M | 86 mo ago | 70 | Asa Abeliovich Founder & CEO | — | 227 patents Developing gene therapy vectors targeting lysosomal storage disease treatments. | — |
| 7 | MindMed Developer of psychedelic-based therapies for brain health disorders | $118M | 27 mo ago | 48 | JR Rahn Co-Founder | WordPressApple iCloud MailMicrosoft 365+17 | — | — |
| 8 | Ovid Therapeutics Developer of therapeutics for rare neurological diseases | $106M | 113 mo ago | 40 40 → 40 (+0%) · sector median +18% | Hongxing Zhou Co-Founder & CEO | WordPress Block EditorWordPressMySQL+19 | 622 patents Patents concentrated in health & consumer products | — |
| 9 | Curemark Developer of therapeutics for the treatment of Autism and other neurological diseases | $93M | 40 mo ago | 9 | — | WordPressMySQLPHP+13 | 269 patents Neuropsychiatric disorder therapeutics and addiction treatment formulations | — |
| 10 | Leal Therapeutics Developer of therapeutics to treat neurological diseases 32Funding top 21%Moat top 42%Talent bottom 49%Market bottom 36% All 5 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $84M | 9 mo ago | 25 | Asa Abeliovich Founder & CEO | — | — | — |
| 11 | Gilgamesh Developer of drugs for neuropsychiatric conditions 62Growth top 15%Funding top 17%Talent top 23%News top 28% All 9 signals ▾Growthtop 15% Fundingtop 17% Talenttop 23% Newstop 28% Moattop 39% AItop 45% Techbottom 40% Globalbottom 39% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $83M | 2 mo ago | 2 | Jonathon Sporn Co-Founder & CEO | WebflowjQueryHSTS+8 | — | — |
| 12 | Intra-Cellular Therapies Developer of therapeutics for psychiatric and neurologic diseases 78Patents top 20%Moat top 23%Funding top 26%Market top 27% All 11 signals ▾Patentstop 20% Moattop 23% Fundingtop 26% Markettop 27% Fin. healthtop 27% Innovationtop 29% Producttop 36% Growthtop 40% Techbottom 46% Globalbottom 42% Newsbottom 23% Patents: 1,493 patents matched (strict assignee match) · 508 filings since 2022 vs 551 in 2017-21 Moat: Top 11% by revenue among 18 tracked Neurology companies · Editorial + unicorn rating 6/10 rank vs industry peers · Fliar Intelligence Index 78/100 | $81M | 13 mo ago | 610 610 → 639 (+5%) · sector median +18% | — | WordPressMySQLPHP+17 | 1,493 patents Novel heterocyclic small‑molecule therapeutics, especially deuterated CNS drug candidates. | — |
| 13 | Acorda Developer of therapies that restore neurological function | $66M | 176 mo ago | 109 | — | — | — | — |
| 14 | JDS Pharmaceuticals Small molecule drugs for psychiatry and women's health | $62M | 261 mo ago | — | Michael Satow Co-founder & CEO | — | — | — |
| 15 | Quentis Therapeutics Developer of therapies for treating cancer and neurodegenerative diseases | $51M | 90 mo ago | 4 | — | — | — | — |
| 16 | Cara Therapeutics Developer of therapeutics for pain relief and inflammatory diseases | $51M | 138 mo ago | 79 | Chris Posner President and CEO | — | 210 patents Novel oral and oligosaccharide delivery systems for kappa opioid receptor agonist therapeutics | — |
| 17 | Linus Biotechnology Developer of diagnostic tests for central nervous system and gastrointestinal disorders | $48M | 22 mo ago | 12 | Paul Curtin Co-Founder | Craft CMSApple iCloud MailGoogle Workspace+18 | 15 patents Molecular exposomics platforms and bio-surface topographic imaging for health monitoring | — |
| 18 | Proneuron Biotechnologies Developer of therapies for spinal cord injury and other neurological conditions | $37M | 232 mo ago | — | Dale S Miller Co-Founder | — | — | — |
| 19 | Cyclo Therapeutics Developer of therapeutics for Niemann-Pick Disease Type C and Alzheimer’s Disease | $32M | 36 mo ago | 9 | N. Scott Fine Chairman & CEO | WordPressMySQLPHP+18 | — | — |
| 20 | Magnolia Neurosciences Developer of therapies for treating neurodegenerative diseases and neuronal injuries | $31M | 94 mo ago | 1 | — | — | — | — |
| 21 | Seelos Therapeutics Developer of therapies for treating CNS disorders and rare diseases | $27M | 45 mo ago | 16 | Raj Mehra Founder & CEO | — | — | — |
| 22 | Palyon Medical Implantable Drug delivery systems for CNS disorders | $24M | 205 mo ago | — | David Present CEO | — | — | — |
| 23 | Remedy Pharmaceuticals Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and… | $23M | 114 mo ago | 6 | — | — | — | — |
| 24 | Empyrean Developer of therapeutics for neuropsychiatric and neurologic diseases | $22M | 44 mo ago | 8 | Usman Azam CEO | — | — | — |
| 25 | Oculogica Eye tracking technology to detect traumatic brain injury (TBI) | $22M | 25 mo ago | 12 | — | WordPressMySQLPHP+48 | 30 patents Eye‑tracking based diagnostic systems for concussion, substance use, and glaucoma detection. | 1 launch |
| 26 | Bioasis A proprietary peptide based delivery platform for developing CNS drugs which can cross the blood-brain barrier | $17M | 60 mo ago | 7 | — | — | 12 patents Engineered fusion protein therapeutics for lysosomal storage diseases, metastatic cancer, and BBB delivery | — |
| 27 | Intrance Medical Systems Developer of therapeutics for the treatment of Parkinson's disease | $17M | 57 mo ago | 3 | Patrick Shea CEO | — | — | — |
| 28 | Redpin Therapeutics Developer of cell therapies for Neurological and Psychiatric disorders | $17M | 75 mo ago | 10 | — | — | — | — |
| 29 | Vaccinex Deveeloper of therapeutics to treat cancer and neurologic diseases | $15M | 26 mo ago | 41 41 → 28 (-32%) · sector median +18% | — | DrupalPHPBootstrap+24 | 576 patents Semaphorin‑4D inhibition and CCR8 antibody therapeutics for neurodegeneration, cognition, and atherosclerosis | — |
| 30 | ProJenX Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS) | $15M | 15 mo ago | 4 | Stan Abel President and Chief Executive Officer | — | — | — |
| 31 | Anavex Developer of therapeutics for neurodegenerative diseases | $14M | 65 mo ago | 40 40 → 47 (+18%) · sector median +18% | Christopher Missling President & CEO | WordPressMySQLPHP+18 | — | — |
| 32 | Axsome Therapeutics Developer of therapeutic solutions for the management of CNS disorders | $13M | 89 mo ago | 545 | — | WordPressMySQLPHP+15 | 671 patents Patents concentrated in health & consumer products | — |
| 33 | Sania Developer of gene therapies to treat neurological diseases | $12M | 25 mo ago | 5 | Rob Brownstone Co-Founder | — | — | — |
| 34 | Reset Pharma Developer of psychedelic treatments for life-threatening illnesses | $11M | 52 mo ago | 5 | Jan-Anders Karlsson Founder / Board member | — | — | — |
| 35 | Mitokinin PINK1-targeted therapies for mitochondria-associated diseases (familial form of Parkinson's Disease) | $10M | 92 mo ago | 19 | Daniel Roulet Co-Founder & CEO | — | 80 patents Patents concentrated in chemistry & materials | — |
| 36 | Avanti Biosciences Biotech innovating therapies for fibrotic, neurodegenerative, inflammatory, and rare metabolic disorders | $9M | 34 mo ago | — | Gian Araldi Founder & CEO | — | — | — |
| 37 | Soterix Medical Neuromodulation and brain stimulation technology for neuropsychiatric and neurological disorders | $9M | 14 mo ago | 37 | Abhishek Datta CEO & CTO | Cart FunctionalityPHPUbuntu+5 | — | — |
| 38 | Oligomerix Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases | $8M | 12 mo ago | 11 | Eliot Davidowitz Co-Founder | — | 55 patents Small-molecule inhibitors targeting tau oligomer formation for neurodegenerative therapeutics | — |
| 39 | Scienture Developer of therapeutics for CNS, oncology, and cardiovascular disease | $6M | 11 mo ago | 6 | — | WordPressMySQLPHP+13 | 24 patents Sustained‑release liquid and injectable drug formulations for cardiovascular and analgesic therapies | 3 launchs |
| 40 | Fisher Wallace Provider of portable brain-stimulating device | $6M | 46 mo ago | 15 | Kelly Roman Co-Founder & CEO | ShopifyShop PayVenmo+27 | — | — |
| 41 | Cytocybernetics Electrophysiology solutions: dynamic clamp, voltage-sensitive dyes, model builder, and analysis | $5M | 47 mo ago | 19 | Glenna Bett Co-Founder & CEO | — | — | — |
| 42 | Neurosity Provider of neural devices and apps for mental health diagnosis and medical intervention | $5M | 44 mo ago | 5 | Alex Castillo CTO & Co-founder | Cart FunctionalityContentfulPHP+24 | 3 patents Brain‑computer interface headwear enabling direct computer control | — |
| 43 | Tonix Pharma Developer of next-generation medicines for CNS and immunological disorders | $4M | 14 mo ago | 117 117 → 169 (+44%) · sector median +18% | — | WordPressMySQLPHP+18 | — | — |
| 44 | Bright Cloud International Devices for neurological rehabilitation therapy | $4M | 81 mo ago | — | Grigore Burdea Founder and Chief Technology Officer | — | — | — |
| 45 | Pharmapotheca A Pharmaceutical development company focused on ADHD, BED, and bariatric diseases | $3M | 69 mo ago | 4 | Harold Meckler President and Co-founder of Pharmapotheca A | — | 14 patents Patents concentrated in health & consumer products | — |
| 46 | Lime Therapeutics Developer of therapeutics for cancer, metabolic diseases, and neurodegenerative disorders | $3M | 26 mo ago | 2 | Daniel Heller Co-Founder | — | — | — |
| 47 | Protagenic Develops neuropeptides for the treatment of anxiety and depression based mood disorders | $3M | 69 mo ago | 2 | — | WordPressMySQLPHP+18 | — | — |
| 48 | DepYmed Developer of therapeutics for rare disease and cancer | $1M | 14 mo ago | 2 | Nicholas Tonks Co-Founder | — | 26 patents Therapeutic copper-chelating agents and aminosteroid PTP1B inhibitors for metabolic disease treatment | — |
| 49 | Sen-Jam Developer of repurposed drugs to treat pain, inflammation and toxin-induced conditions | $480K | 16 mo ago | 10 | Jim Iversen Co-Founder CEO | — | — | — |
| 50 | Akelos Biotechnology firm pioneering non-opioid neuropathic pain treatments | $320K | 3 mo ago | 4 | Steven Fox Founder | — | — | — |
Top 12 Neurology companies in New York
#1
Series B · New York City, New York · founded 2019 · 2 employees$83.1Mraised▾
Series B · New York City, New York · founded 2019 · 2 employees
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 15%Funding
top 17%Talent
top 23%News
top 28%Moat
top 39%AI
top 45%Growth: Fresh capital in last 24 mo
Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) · Last round Series B (Mar 2026)
Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Audience (LinkedIn): 11k LinkedIn followers — 3.9% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CMC - Drug Substance professional
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. AbbVie) announced in 12 mo
Funding rounds
- Mar 2026Series B$2.2M
- Mar 2026Series B$60M
- Jan 2026Series B$6.1M
- May 2025Grant (prize money)$5.4M
Founders & team
Investors
Prime Movers Lab, Noetic Psychedelic Fund, Gron Ventures, Route 66 Ventures, JLS Fund, Palo Santo
Tech stack
CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#2
Public · New York City, New York · founded 2015$130.1Mraised▾
Public · New York City, New York · founded 2015
Developer of small molecule based therapeutics for schizophrenia. The company's lead product candidate LB-102, also known as N-methyl amisulpride, is very similar to the marketed antipsychotic amisulpride and differs by only one methyl group (CH3). The drug acts as an antagonist to dopamine (D2, D3), and 5-HT7 receptors and exerts the antipsychotic effect.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Moat
top 21%Growth
top 23%Patents
top 25%News
top 27%Funding
top 30%Innovation
top 34%Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Patents: 437 patents matched (strict assignee match) · 172 filings since 2022 vs 251 in 2017-21 · Latest publication 2026
Funding rounds
- Feb 2026Post IPO$100M
- Aug 2023Series C$110.7M
- Aug 2020Series B$10M
- Mar 2019Series A$1.6M
Founders & team
Investors
Tarnagulla Ventures
#3
Public · New York City, New York · founded 2018 · 58 employees$185Mraised▾
Public · New York City, New York · founded 2018 · 58 employees
Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases. It has developed a lead candidate LX1001 APOE4 inhibitor that helps in treating Alzheimer’s andother neurological disorders. Its drug candidate LX2006 cardiomyopathy helps in the treatment of Friedreich’s Ataxia & other genetic disorders. It also provides LX1004 CLN2 drug that plays an important role in treating Batten disease.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%News
top 43%Growth
top 47%Tech
bottom 49%Talent
bottom 40%Global
bottom 39%Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) · Last round Post IPO (Oct 2025)
News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 6.0% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Post IPO$10M
- May 2025Post IPO$80M
- Mar 2024Post IPO$95M
- Aug 2023Series B—
Founders & team
Investors
Sarepta, Longitude Capital, Omega Funds, PBM Capital, Lundbeck Foundation, Janus Henderson Investors
Tech stack
Apache Http ServerDreamhostGoogle AnalyticsGoogle MapsGoogle Tag ManagerJquery
#4
Series D · Brooklyn, New York · founded 2016 · 53 employees$145Mraised▾
Series D · Brooklyn, New York · founded 2016 · 53 employees
Developer of implantable bioelectronics for the treatment of neurological conditions. The company offers a motor neuroprosthesis the Stentrode which helps paralyzed patients regain the ability to communicate. Also, provides endovascular neuromodulation minimally invasive device that stimulates brain or nerve activity for the treatment of Parkinson’s disease, epilepsy, depression, and others.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 17%News
top 30%Talent
top 38%Growth
top 47%Moat
top 48%Market
bottom 46%Funding: Raised $145M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) · Last round Series D (Nov 2025)
News: 3 BI events in 12 mo (of 14 tracked, 7 types) · Top themes: Funding, Capital raise
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 44k LinkedIn followers — 15.0% of this cohort's audience · 78 engagements/post (1.5× cohort median)
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: R&D Manager, Senior Director, Regulatory Affairs-CA
Funding rounds
- Nov 2025Series D$200M
- Dec 2022Series C$75M
- Dec 2021Grant (prize money)$990K
- Aug 2021Grant (prize money)$10M
Founders & team
Investors
Future Fund, Khosla Ventures, Shanda, Forepont Capital Partners, ID8 Investments, General Advance
Tech stack
Apache Http ServerApple Icloud MailBarba.JsCore-JsCraft CmsGodaddy
#5
Series C · New York City, New York · founded 2021 · 22 employees$173.8Mraised▾
Series C · New York City, New York · founded 2021 · 22 employees
Developed of brain-computer interface tool for medical treatment and drug development. The company has developed a next-generation brain computing technology that has the ability to process medicine and computing. The brain implants have features for AI-based computing, device integration, and assessment of neurological illness for medicine development.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Talent
top 38%Tech
top 39%AI
top 45%Growth
bottom 40%Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 38k LinkedIn followers — 13.1% of this cohort's audience · 77 engagements/post (1.5× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Field Clinical Specialist, VP, Market Access
Activity (LinkedIn): 2 product launches · 1 awards announced in 12 mo
Funding rounds
- Nov 2025Series C—
- Jan 2025Series C—
- Oct 2024Series C$102M
- Mar 2024Series B$27.5M
Founders & team
Investors
Steadview, B Capital, General Equity Holdings, Duquesne Family Office, Forepont Capital Partners, Mubadala
Tech stack
Apple Icloud MailBase UiCloudflareCloudflare Bot ManagementCookieyesDocusign
#6
Series A · New York City, New York · founded 2021 · 25 employees$84Mraised▾
Series A · New York City, New York · founded 2021 · 25 employees
Developer of therapeutics to treat neurological diseases. The company is advancing precision therapeutics for genetic targets to address severe CNS disorders.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 21%Moat
top 42%Talent
bottom 49%Market
bottom 36%Global
bottom 29%Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series A (Aug 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Aug 2025Series A$30M
- Oct 2024Series A$45M
- Feb 2024Seed$39M
Founders & team
Investors
Newpath Partners, Chugai Venture Fund, Alexandria, Orbimed, PhiFund Ventures, Euclidean Capital
#7
Acquired · New York City, New York · founded 2002 · 610 employees$80.9Mraised▾
Acquired · New York City, New York · founded 2002 · 610 employees
Developer of therapeutics for psychiatric and neurologic diseases. The company’s product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. It also developed a state of the art technology platform, called CNSProfil that is capable of generating a unique molecular signature for drug compounds.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Patents
top 20%Moat
top 23%Funding
top 26%Market
top 27%Fin. health
top 27%Innovation
top 29%Patents: 1,493 patents matched (strict assignee match) · 508 filings since 2022 vs 551 in 2017-21 · Latest publication 2026
Moat: Top 11% by revenue among 18 tracked Neurology companies · Editorial + unicorn rating 6/10 · IP moat: 1,493 patents
Funding: Raised $80.9M across 11 rounds · 11 rounds over 16 yrs (0.7/yr) · Last round Grant (prize money) (Apr 2025)
Audience (LinkedIn): 37k LinkedIn followers — 12.6% of this cohort's audience
Funding rounds
- Apr 2025Grant (prize money)$6.2M
- Jan 2025Grant (prize money)$6.2M
- Jul 2014Grant (prize money)$318.9K
- Aug 2013Series C$60M
Investors
HHS, Military Health, Tech Council Ventures, Alafi Capital, BB Biotech, NJTC Venture Fund
Tech stack
AccessibeAll In One SeoCloudflareCloudflare Browser InsightsCore-JsGoogle Analytics
#8
Series B · New York City, New York · founded 2006 · 11 employees$7.9Mraised▾
Series B · New York City, New York · founded 2006 · 11 employees
Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases . It has developed two approaches for small molecule drug discovery tau oligomer inhibitor program and tau protease inhibitor program. Its drugs target neurotoxic tau oligomers that impair learning and memory and that cause spread of Alzheimer’s and related neurodegenerative diseases in the brain.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- May 2025Grant (prize money)$4.6M
- Nov 2024Conventional Debt$75K
- Sep 2022Grant (prize money)$2.5M
- Aug 2022Grant (prize money)$3.4M
Founders & team
Investors
NIH, NIA, Wheatley Partners, SBIR, HHS, Counterview Capital
Tech stack
WordpressMysqlPhpAnimate.CssWp RocketBreadcrumb Navxt
#9
Public · Hauppauge, New York · founded 2019 · 6 employees$6Mraised▾
Public · Hauppauge, New York · founded 2019 · 6 employees
Developer of therapeutics for CNS, oncology, and cardiovascular disease. The company's lead candidates include SCN-101, SCN-104, and SCN-105 are used to treat CNS disease, SCN-102 is for oncology, and SCN-103 and SCN-106 are used to treat cardiovascular disease. The company is also developing therapeutics including SCN- 07 for pain, SCN-108 for endocrinology, and SCN-109 for anti-infective diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 637 LinkedIn followers
Activity: 3 product launches announced in 12 mo
Funding rounds
- Jul 2025Post IPO$1.7M
- Nov 2024Post IPO$3.3M
- Dec 2020Post IPO$6M
#10
Series A · New York City, New York · founded 2020 · 12 employees$47.6Mraised▾
Series A · New York City, New York · founded 2020 · 12 employees
Developer of diagnostic tests for central nervous system and gastrointestinal disorders. The company offers StrandDx ASD, a non-invasive diagnostic aid for Autism Spectrum Disorder. The company's pipeline comprises precision exposome medicine biomarkers and target discovery across gastroenterology, renal disease and oncology.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Jul 2024Series A$6.1M
- May 2023Series A$8M
- Jan 2023Series A$16M
- Mar 2022Series A$17.5M
Founders & team
Investors
Yac, GreatPoint Ventures, Bow Capital, Divergent Investments
Tech stack
Alpine.JsApple Icloud MailBlitzBunnyCloudflareCraft Cms
#11
Series A · New York City, New York · founded 2021 · 4 employees$15Mraised▾
Series A · New York City, New York · founded 2021 · 4 employees
Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS). The lead therapeutic candidate "Prosetin", is an oral, brain-penetrant, MAP4 kinase inhibitor targeting endoplasmic reticulum (ER) stress-mediated motor neuron death for the treatment of people with Amyotrophic lateral sclerosis (ALS).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 721 LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$2.2M
- Nov 2023Series A$15M
- Seed—
Founders & team
Investors
Medical Excellence Capital, Military Health
#12
Funding Raised · New York City, New York · founded 2008 · 37 employees$8.5Mraised▾
Funding Raised · New York City, New York · founded 2008 · 37 employees
Neuromodulation and brain stimulation technology for neuropsychiatric and neurological disorders. It pioneers innovative medical treatments using non-invasive neuromodulation and integrated brain monitoring technology. The company develops and deploys solutions for clinical trials, offering unique and adaptable systems for clinicians and patients. Their portfolio includes transcranial Direct Current Stimulation (tDCS), High-Definition tDCS (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. They distribute synergistic technologies and provide services in image analysis, modeling, and human factors. The company is committed to bringing advanced medical technology to those who need it, focusing on research systems, clinical systems, software, and pre-clinical support. They offer platforms for tDCS, tES, Transcranial Magnetic Stimulation (TMS), Transcranial Focused Ultrasound Stimulation (tFUS), functional Near Infrared Spectroscopy (fNIRS), and mobile EEG, supported by software for neurotargeting and modeling services.
Funding rounds
- Mar 2025Grant (prize money)$956.9K
- Sep 2021Grant (prize money)$956.9K
- Aug 2021Grant (prize money)—
- Jun 2016Grant (prize money)$2.5M
Founders & team
Investors
NINDS, HHS
Tech stack
Apache Http ServerBootstrapCart FunctionalityGoogle AdsGoogle Ads Conversion TrackingGoogle Analytics
Funding & investor landscape
$2.2Btotal disclosed funding
66companies funded
283disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Jonathon Sporn
Co-Founder & CEO · Gilgamesh
Andrew Kruegel
Co-Founder · Gilgamesh
Zachary Prensky
Founder & CEO · LB Pharmaceuticals
Nolan Townsend
CEO · LEXEO Therapeutics
Rahul Sharma
Co-Founder · Synchron
Thomas Oxley
CEO · Synchron
Benjamin Rapoport
Co-Founder & CSO · Precision Neuroscience
Michael Mager
Co-Founder and Chief Executive Officer · Precision Neuroscience
Asa Abeliovich
Founder & CEO · Leal Therapeutics
Eliot Davidowitz
Co-Founder · Oligomerix
James Moe
Co-Founder & CEO & President · Oligomerix
Paul Curtin
Co-Founder · Linus Biotechnology
Prism market signals · United States · country-scoped Prism corpus, 672,586 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
Common questions
How many Neurology companies are there in New York, United States?
Radar tracks 109 indexable Neurology companies headquartered in New York, United States that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in New York, United States?
The Neurology companies in New York, United States on this list have raised a combined $2.2B in disclosed equity funding across 66 funded companies.
Which is the highest-funded Neurology company in New York, United States?
LEXEO Therapeutics is the highest-funded Neurology company in New York, United States, with $185M in disclosed equity funding.
How many Neurology companies in New York, United States are funded?
66 of the 109 Neurology companies in New York, United States on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in New York, United States?
None of the Neurology companies in New York, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in New York, United States Neurology companies?
The most active investors in New York, United States Neurology companies on this list include HHS, NIH, Alexandria, AbbVie, JLABS.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.